151 results on '"Majo, Fabio"'
Search Results
2. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
3. Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
4. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults
5. Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype
6. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation
7. Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study
8. Use of Lung Ultrasound in Cystic Fibrosis: Is It a Valuable Tool?
9. A novel mutation in GAS8 gene associated with chronic rhinosinusitis with nasal polyposis in a case of primary ciliary dyskinesia: a case report.
10. Rates of depression and anxiety in Italian patients with cystic fibrosis and parent caregivers: Implementation of the Mental Health Guidelines
11. Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function
12. Corrigendum to “Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor”. J Pediatr. 2024 Jun 28; 274:114176
13. Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.
14. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor
15. Pancreatic disorders in children: New clues on the horizon
16. Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial
17. Endotypes of Nasal Polyps in Children: A Multidisciplinary Approach
18. Management of respiratory tract exacerbations in people with cystic fibrosis:Focus on imaging
19. Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging
20. Clinical outcome of individuals carrying 5T;TG12 in trans with CFTR variants with varying clinical consequences
21. Aryl Hydrocarbon Receptor Agonism Antagonizes the Hypoxia-driven Inflammation in Cystic Fibrosis
22. Heterogeneity of weight gain after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
23. Clinical outcome of individuals carrying 5T;TG12 in trans with CFTR variants with varying clinical consequences
24. State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the'iMAging managEment of cySTic fibROsis' (MAESTRO) consortium
25. Aryl Hydrocarbon Receptor Agonism Antagonizes the Hypoxia-driven Inflammation in Cystic Fibrosis.
26. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
27. State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the “iMAging managEment of cySTic fibROsis” (MAESTRO) consortium
28. Liposomes loaded with bioactive lipids enhance antibacterial innate immunity irrespective of drug resistance
29. Glucose tolerance affects pubertal growth and final height of children with cystic fibrosis
30. Disease characterization of people with cystic fibrosis and a minimal function mutation: Data from the Italian registry
31. Nuclear Magnetic Resonance-based Metabolomics Discriminates Primary Ciliary Dyskinesia from Cystic Fibrosis
32. Hypoxia Promotes Danger-mediated Inflammation via Receptor for Advanced Glycation End Products in Cystic Fibrosis
33. Abstracts from the 23rd Italian congress of Cystic Fibrosis and the 13th National congress of Cystic Fibrosis Italian Society
34. Expectations about CFTR modulators among physicians from Italian Cystic fibrosis centers: a survey about the evolution of clinical practice paradigms for cystic fibrosis
35. Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology
36. Defining research priorities in cystic fibrosis. Can existing knowledge and training in biomedical research affect the choice?
37. Cystic fibrosis with non‐G551D gating mutations in Italy: Epidemiology and clinical characteristics
38. Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial
39. Registro Italiano Fibrosi cistica Rapporto 2011-2014
40. GH-IGF-1 Axis in Children with Cystic Fibrosis
41. Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
42. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry
43. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype
44. Cystic fibrosis with non‐G551D gating mutations in Italy: Epidemiology and clinical characteristics.
45. Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis
46. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.
47. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians
48. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis
49. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry.
50. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.